Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (d,l-lactide-co-glycolide) microspheres

Allaoui-Attarki, Khadija; Fattal, Elias; Pecquet, Sophie; Trollé, Sylvine; Chachaty, Élisabeth; Couvreur, Patrick; Andremont, Antoine

doi:10.1016/s0264-410x(97)00261-2

Cited by 41 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has provided the impetus for active studies to design biodegradable materials and approaches for delivery by different routes of administration (14)(15)(16)(17). Benefits of controlled release systems are delivery to a specific site, protection of the antigen from degradation, better patient compliance and more efficient antigen dosing, which may eliminate the need for boosters.…”

Section: Controlled Delivery Systemsmentioning

confidence: 99%

“…Among the polymeric systems developed for pharmaceutical proposals, poly-lactideco-glycolide (PLGA) microspheres have been widely explored in several immuno-logical studies as a controlled delivery system of peptides, native and synthetic proteins and lately, nucleic acids (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). PLGA microspheres are composed of a sphericalshaped polymeric matrix ranging in diameter from 1 to 250 µm (Figure 1).…”

Section: Poly-lactide-co-glycolide Microspheresmentioning

confidence: 99%

“…The maintenance of immunogenicity after antigen contact with organic solvents is also an important aspect to consider. Many studies have indicated that the antigenic properties and the structure of the proteins can be preserved during entrapment (26,44,(49)(50)(51)(52)(53). Another important aspect is related to the possibility of scaling up the process under aseptic conditions, allowing the preparation of a pyrogen-free and sterile product (54).…”

Section: Microsphere Preparationmentioning

confidence: 99%

See 2 more Smart Citations

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Lima

Júnior

1999

Braz J Med Biol Res

View full text Add to dashboard Cite

Successful vaccine application means maximum protection with minimal number of administrations. A rational development of vaccines involves studies of the nature of the antigen as well as of the adjuvant to be used to improve the immune responses. This has provided the impetus for studies to design the degradable devices and for different approaches to antigen delivery by different routes of administration. The development of controlled release systems based on polymeric devices that permit a sustained or pulsed release of encapsulated antigens has attracted much interest. Polymeric delivery systems consist of polymers that release their content continuously in a controlled manner over a period of time. The development of a biocompatible delivery system for parenteral administration offers several advantages in terms of immunoadjuvanticity over other compounds. It was found that, in contrast to other carriers, microspheres are more stable, thus permitting administration by the oral or parenteral route. In the present study, we describe the main characteristics and potentialities of this new immunoadjuvant for oral and parenteral administration. Correspondence

show abstract

Section: Controlled Delivery Systemsmentioning

confidence: 99%

Section: Poly-lactide-co-glycolide Microspheresmentioning

confidence: 99%

Section: Microsphere Preparationmentioning

confidence: 99%

See 1 more Smart Citation

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Lima

Júnior

1999

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…Mucosal immunization with antigens encapsulated in PLG microparticles protected animals against challenge with mucosal pathogens. Mice orally immunized with antigen in PLG microparticles were better protected against oral challenge with S. typhimurium, than those immunized intraperitoneally (IP) with antigen in Freund's adjuvant [3,45]. Interestingly, a single oral immunization with fimbriae from Bordetella pertussis encapsulated in PLG microparticles protected mice from intranasal challenge with the bacteria [76], indicating that the microparticle delivery system effectively stimulated the common mucosal immune system to protect against infection at a distant mucosal site.…”

Section: Polymersmentioning

confidence: 99%

Mucosal delivery of vaccines in domestic animals

et al. 2006

View full text Add to dashboard Cite

-Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although highly beneficial for achieving protective immunity, the induction of mucosal immunity, especially in the gastro-intestinal tract, still remains a difficult task. As a result, only very few mucosal vaccines are commercially available for domestic animals. Here, we critically review various strategies for mucosal delivery of vaccines in domestic animals. This includes live bacterial and viral vectors, particulate delivery-systems such as polymers, alginate, polyphosphazenes, immune stimulating complex and liposomes, and receptor mediated-targeting strategies to the mucosal tissues. The most commonly used routes of immunization, strategies for delivering the antigen to the mucosal surfaces, and future prospects in the development of mucosal vaccines are discussed. mucosal / vaccine / livestock / animals / review

show abstract

“…22,23 A number of studies have reported improved antibody responses when antigens are orally administered in PLGA particles. [24][25][26][27] Nevertheless, PLGA NPs have limited use in mucosal vaccination because of their poor mucoadhesivity and immunoenhancing ability. In recent years, chitosan (CS) has been used as a coating material for PLGA NPs because of its biological adhesive properties and ability to improve the immunological response to mucosal vaccination.…”

Section: Introductionmentioning

confidence: 99%

Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine

Zhao¹,

Zhang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

We determined the efficacy and safety of chitosan (CS)-coated poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) as a delivery system for a vaccine to protect chickens against Newcastle disease virus (NDV). The newly constructed vaccine contained DNA (the F gene) of NDV. The Newcastle disease virus (NDV) F gene deoxyribonucleic acid (DNA) plasmid (pFDNA)-CS/PLGA-NPs were spherical (diameter =699.1±5.21 nm [mean ± standard deviation]) and smooth, with an encapsulation efficiency of 98.1% and a Zeta potential of +6.35 mV. An in vitro release assay indicated that CS controlled the burst release of plasmid DNA, such that up to 67.4% of the entire quantity of plasmid DNA was steadily released from the pFDNA-CS/PLGA-NPs. An in vitro expression assay indicated that the expression of nanoparticles (NPs) was maintained in the NPs. In an immunization test with specific pathogen-free chickens, the pFDNA-CS/PLGA-NPs induced stronger cellular, humoral, and mucosal immune responses than the plasmid DNA vaccine alone. The pFDNA-CS/PLGA-NPs did not harm 293T cells in an in vitro assay and did not harm chickens in an in vivo assay. Overall, the results indicated that CS-coated PLGA NPs can serve as an efficient and safe mucosal immune delivery system for NDV DNA vaccine.

show abstract

Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (d,l-lactide-co-glycolide) microspheres

Cited by 41 publications

References 36 publications

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system

Mucosal delivery of vaccines in domestic animals

Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine

Contact Info

Product

Resources

About